WHO ICTRP trial
ROMANCE
CTIS2025-521319-38-00 · EU Clinical Trials Information System · Not Recruiting
Key facts
| Trial ID | CTIS2025-521319-38-00 |
|---|---|
| Public title | ROMANCE |
| Scientific title | A phase II, open label, multicenter trial investigating Irinotecan plus cetuximab rechallenge compared with trifluridine/tipiracil plus bevacizumab as third line treatment in circulating tumor DNA molecularly selected metastatic colorectal cancer: the ROMANCE-GOIM trial |
| Primary sponsor | Gruppo Oncologico Dell'Italia Meridionale |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): Yes Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): No |
| Countries | Italy |
| Conditions | metastatic colorectal cancer;Therapeutic area: Diseases [C] - Neoplasms [C04] |
| Interventions | Product Name: BEVACIZUMAB, Product Code:SUB16402MIG, Pharmaceutical Form: CONCENTRATE FOR SOLUTION FOR INFUSION, Other descriptive name: , Strength: , Product Name: IRINOTECAN, Product Code:SUB08295MIG, Pharmaceutical Form: CONCENTRATE FOR… |
| Registration date | Mar 10, 2025 |
| Target size | 150 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: